SciNeuro: Funding, Investors & Team (Sep 2026)
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.
SciNeuro has raised $53.0M across 1 funding round on record, the most recent an undisclosed round of $53.0M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SciNeuro Company Profile and Key Stats
Latest funding round on record: Dec 2025.
SciNeuro Funding Rounds
SciNeuro Founders and Leadership Team
Contact details for the SciNeuro team: 1 of 1 has an email address on file.
Start 14-day free trial →SciNeuro Funding Compared to Other Biotechnology Startups
SciNeuro's latest round of $53.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SciNeuro in Biotechnology and Rockville
Companies Similar to SciNeuro
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
SciNeuro Funding FAQs
What does SciNeuro do?
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.
How much funding has SciNeuro raised?
SciNeuro has raised $53.0M across 1 round on record. The most recent is an undisclosed round of $53.0M announced in Dec 2025.
When did SciNeuro last raise funding?
SciNeuro's most recent funding round on record is an undisclosed round of $53.0M, announced in Dec 2025.
Who founded SciNeuro?
FundedIQ lists Min Li (Founder) at SciNeuro.
Where is SciNeuro headquartered?
SciNeuro is based in Rockville, Maryland, United States.
How many employees does SciNeuro have?
SciNeuro is in the 11-50 employee band.
How does SciNeuro's funding compare to other Biotechnology startups?
SciNeuro's latest round of $53.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's SciNeuro Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SciNeuro is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.